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Introduction: Rheumatoid arthritis (RA) is a complex polygenic disease associated with chronic inflammation,
accelerated atherosclerosis and increased cardiovascular (CV) mortality. A recent meta-analysis has described the
ZC3HC1 rs11556924 polymorphism as one of the most important signals associated with coronary artery disease
(CAD) in non-rheumatic Caucasian individuals. In this study we evaluated the potential association of this gene
polymorphism with subclinical atherosclerosis assessed by the evaluation of carotid intima-media thickness (cIMT)
in RA patients.
Methods: This study included 502 RA patients from Northern Spain. The ZC3HC1 rs11556924 polymorphism was
genotyped with TaqMan single-nucleotide polymorphism (SNP) genotyping assays (C__31283062_10) in a 7900HT
real-time polymerase chain reaction (PCR) system. cIMT was also assessed in these patients by carotid
ultrasonography (US) technology.
Results: RA patients carrying the TT genotype had significantly higher cIMT values than those homozygous for the
CC genotype (mean ± standard deviation (SD): 0.76 ± 0.18 mm and mean ± SD: 0.71 ± 0.16 mm respectively; P = 0.03)
even after adjusting the results for sex, age at the time of US study, follow-up time and traditional CV risk factors
(P = 0.04) evidencing that the effect conferred by ZC3HC1 rs11556924 polymorphism is independent of the traditional
CV risk factors.
Conclusion: Our results indicate that ZC3HC1 rs11556924 polymorphism is associated with subclinical atherosclerosis
in RA.Introduction
Rheumatoid arthritis (RA) is a complex inflammatory dis-
ease associated with increased risk of cardiovascular (CV)
disease and CV mortality that is the result of accelerated
atherosclerosis [1,2]. Because of that, adequate stratifica-
tion of the CV risk has special relevance in patients with
RA. Besides traditional CV risk factors and chronic in-
flammation [3], recent studies have also highlighted the* Correspondence: miguelaggay@hotmail.com
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distribution, and reproduction in any mediumimplication of genetic factors and the influence of several
gene polymorphisms in the susceptibility to and/or in the
risk of accelerated atherosclerosis of patients with RA [4].
Since CV disease is the most common cause of premature
mortality in RA, an important step forward might be to
identify high-CV risk RA patients who would benefit from
active therapy to prevent the development of CV
complications.
Subclinical atherosclerosis has been observed in pa-
tients with RA [5], even in those without traditional CV
risk factors [5]. Several validated noninvasive imaging
techniques are currently available to determine subclin-
ical atherosclerosis in RA. They can offer a unique op-
portunity to study the relation of surrogate markers toentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Demographic and clinical characteristics of the
Spanish patients with RA included in the study
Clinical feature % (n/N)
Patients 502
Main characteristics
Age at the time of disease onset (years, mean ± SD) 50.8 ± 14.5
Follow-up (years, mean ± SD) 9.5 ± 8.1
Percentage of women 77.7
Rheumatoid factor positivea 60.6 (297/490)
Anti-CCP antibodies positive 51.9 (227/437)
Shared epitope positive 62.1 (179/288)
Extra-articular manifestationsb 21 (107/502)
Cardiovascular risk factors
Hypertension 22.7 (110/484)
Diabetes mellitus 6.6 (32/484)
Dyslipidemia 15.1 (73/484)
Obesity 9.7 (47/484)
Smoking habit 27.9 (135/484)
Patients with cardiovascular events 10.7 (54/502)
Ischemic heart disease 4.6 (23/502)
Heart failure 1.9 (10/502)
Cerebrovascular accident 3.8 (19/502)
Peripheral arteriopathy 1.2 (6/502)
aAt least two determinations were required; bextra-articular manifestations of
the disease (if RA patients experienced at least one of the following
manifestations: nodular disease, Felty’s syndrome, pulmonary fibrosis,
rheumatoid vasculitis, or secondary Sjögren’s syndrome) [12]. Anti-CCP
antibodies, anti-cyclic citrullinated peptide antibodies; RA, rheumatoid arthritis;
SD, standard deviation.
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the assessment of carotid intima-media thickness (cIMT),
carotid ultrasonography (US) has become an affordable ef-
ficient technique to measure the presence of subclinical
atherosclerosis. A meta-analysis encompassing several
population based studies confirmed an increased cIMT in
RA patients when compared with the general population
[7]. Interestingly, as observed in the general population,
abnormally high values of cIMT (greater than 0.90 mm)
have been found to predict the development of CV events
in patients with RA after five years of follow-up [8].
Recently, a meta-analysis of 14 genome-wide association
studies of coronary artery disease (CAD) performed in
non-rheumatic Caucasian individuals has identified 13
novel loci harboring one or more polymorphisms that
were associated with this pathology and confirmed the
association of 10 of 12 previously reported CAD loci
[9]. With respect to this, the genetic variant rs11556924
(C > T) that is located at 7q32.2 and encodes a non-
synonymous change (R363H) in the ZC3HC1 (zinc finger,
C3HC-type containing 1) gene, seems to be one of the
most significant signals associated with CAD in non-
rheumatic Caucasian individuals [9].
Taking all these considerations into account, in the
present study we aimed to determine, for the first time, the
potential association between the ZC3HC1 rs11556924
polymorphism (as a marker of CV disease) and subclinical
atherosclerosis manifested by the increase of cIMT in pa-
tients with RA.
Methods
Patients and study protocol
A total of 502 Spanish patients with RA from Northern
Spain were included in the present study. Blood samples
were obtained from patients recruited from Hospital
Lucus Augusti (Lugo) and Hospital Marqués de Valdecilla
(Santander). Ethics Committees of Cantabria for Hospital
Universitario Marqués de Valdecilla in Santander and
Galicia for Hospital Lucus Augusti in Lugo approved
the work. Patients gave the necessary written consent,
including consent to participate in the study and con-
sent to publish the results.
All the patients fulfilled the 1987 American College of
Rheumatology (ACR) and also the 2010 classification
criteria for RA [10,11]. In all the cases, patients were
assessed for the ZC3HC1 rs11556924 polymorphism.
Information on the main demographic and clinical
characteristics of the patients enrolled in the study,
CV risk factors and CV events of these patients is
shown in Table 1. Definitions of CV events (ischemic
heart disease, heart failure, cerebrovascular accident
or peripheral arteriopathy) and definitions of trad-
itional CV risk factors were established as previously
described [8,12].Genotyping
DNA from patients was obtained from peripheral blood
using standard methods.
The ZC3HC1 rs11556924 polymorphism was genotyped
with TaqMan predesigned single-nucleotide polymorph-
ism (SNP) genotyping assays (C__31283062_10) in a 7900
HT Real-Time polymerase chain reaction (PCR) system,
according to the conditions recommended by the manu-
facturer (Applied Biosystems, Foster City, CA, USA).
Negative controls and duplicate samples were included to
check the accuracy of genotyping.
Carotid ultrasonography examination
Patients from Santander were assessed using a commer-
cially available scanner, Mylab 70, Esaote (Genoa, Italy)
equipped with a 7 to 12 MHz linear transducer and the
automated software guided technique radiofrequency—
Quality Intima Media Thickness in real-time (QIMT,
Esaote, Maastricht, Holland)—was used [13]. Patients
from Lugo were assessed using high-resolution B-mode
ultrasound, Hewlett Packard SONOS 5500, with a 10-
MHz linear transducer as previously reported [14]. cIMT
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mon carotid arteries, 10 mm from the carotid bifur-
cation, over the proximal 15 mm-long segment. cIMT
was determined as the average of three measurements in
each common carotid artery. The final cIMT was the
largest average cIMT (left or right). Agreement between
the two US methods in patients with RA was previously
reported [15]. Two experts with extensive experience
and close collaboration in the assessment of cIMT in
RA from Santander (AC) and Lugo (CGJ) performed the
studies.
Statistical analysis
Results are displayed as mean and standard deviation
(SD). The association between the genotypes of the
ZC3HC1 rs11556924 polymorphism and cIMT values
was tested using the Mann–Whitney test to compare be-
tween two groups. Comparisons of means was adjusted
for sex, age at the time of the US study, follow-up time
and traditional CV risk factors (hypertension, diabetes
mellitus, dyslipidemia, obesity, and smoking habit) as
potential confounders using analysis of covariance
(ANCOVA).
Statistical significance was defined as P ≤0.05, and all
analyses were performed using STATA statistical soft-
ware 12/SE (Stata Corp., College Station, TX, USA).
Results
The genotyping success was 99% and ZC3HC1 rs11556924
genotype distribution was in Hardy-Weinberg equilibrium.
Results of the comparison between the different geno-
types of ZC3HC1 rs11556924 polymorphism according
to cIMT are shown in Table 2. RA patients carrying the
TT genotype had significantly higher cIMT values than
those homozygous for the CC genotype (mean ± SD:
0.76 ± 0.18 mm and mean ± SD: 0.71 ± 0.16 mm, respect-
ively; P = 0.03) while patients carrying the CT genotype
had intermediate cIMT values (mean ± SD: 0.73 ± 0.17
mm) (CT versus CC P = 0.16).
Since sex, age at the time of US study, follow-up time
and traditional CV risk factors (hypertension, diabetes
mellitus, dyslipidemia, obesity, and smoking habit) mayTable 2 Association between ZC3HC1 rs11556924
genotypes and carotid intima-media thickness (cIMT) in
RA patients
cIMT mm mean ± SD (n) P
ZC3HC1 rs11556924
Genotype distribution
CC 0.71 ± 0.16 (175) Ref.
CT 0.73 ± 0.17 (244) 0.16
TT 0.76 ± 0.18 (83) 0.03
RA, rheumatoid arthritis; SD, standard deviation.act as potential confounders of the results derived from
the US assessment, adjustment for these potential con-
founders was performed using an ANCOVA model.
Interestingly, even after adjusting for potential con-
founders, patients carrying the TT genotype had signifi-
cantly higher cIMT values than those carrying the CC
genotype (P = 0.04) showing that the effect conferred by
the ZC3HC1 rs11556924 polymorphism is independent
of the traditional CV risk factors.
Discussion
Cardiovascular disease is the most common cause of pre-
mature mortality in patients with RA, being a conse-
quence of accelerated atherosclerosis [1]. The augmented
CV mortality observed in this pathology is the result of a
compound effect mediated by traditional CV risk factors,
chronic inflammation [3] and the genetic component [4].
Since genes have been associated with an increased risk of
CV disease in RA [4], in recent years several studies have
been focused on the search for genetic markers that may
improve the identification of RA patients at risk of experi-
encing CV events. Interestingly, cIMT has been proposed
to be a good predictor of CV events in low and intermedi-
ate CV risk groups of non-rheumatic individuals and also
in RA patients [8]. Also, a recent study has supported the
use of carotid US in the assessment of the CV risk of RA
patients [13].
A large-scale study has disclosed several loci associ-
ated with CAD [9]. Interestingly, in this study the
ZC3HC1 rs11556924 polymorphism was associated with
CAD in non-rheumatic Caucasian individuals [9]. There-
fore, in spite of having a moderate effect on CAD as com-
pared to other genetic variants described by Schunkert
et al., such as polymorphisms in CDKN2A, SORT1, LDLR,
MRPS6 and MIA3 [9], we assessed this time the ZC3HC1
rs11556924 polymorphism because we had already ana-
lyzed the potential role of some others. In this regard, we
previously showed that the rs599839 polymorphism lo-
cated in the lp13.3 genomic region (SORT1) was associ-
ated with endothelial dysfunction in RA [16]. In addition,
we reported an association between MIA3 rs17465637
A allele with the risk of CV events in RA patients with
dyslipidemia [17]. The assessment of the potential influ-
ence of other polymorphisms in the risk of CV disease in
RA, such as CDKN2A and CDKN2B, LDLR, MRPS6,
PPAP2B and ADAMST7, among others, is still underway.
ZC3HC1 (zinc finger, C3HC-type containing 1), also
called NIPA (nuclear interaction partner of ALK), is a
mammalian F-box-like protein [18] that monitors the tim-
ing of mitotic entry and in complex with constitutively ac-
tive oncogenic proteins contributes to the development of
carcinogenesis [19]. Since it has been shown that media-
tors of angiogenesis may play an important role in the
regulation of endothelial integrity and inflammation [20],
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properties of ZC3HC1 protein may play a role in the
endothelial dysfunction and, in the long run, in the devel-
opment of atherosclerosis.
Since the incidence of CV disease is increased in pa-
tients with RA, we assessed for the first time the poten-
tial association between this polymorphism (as a marker
of CV disease) and subclinical atherosclerosis in RA.
Our results show that RA patients carrying the TT geno-
type have significantly higher cIMT values than those RA
patients carrying the CC genotype, even after adjusting for
potential confounders, supporting the evidence that the
genetic component plays a relevant role in the develop-
ment of CV disease in RA [4]. These results showing an
association with the TT genotype apparently seem to be in
contradiction with the data described by Schunkert et al.
that reported an association of the C allele with the risk of
CAD [9]. However, it is important to highlight that the
populations analyzed in our study and in the study by
Schunkert et al. are different. In this regard, Schunkert
et al. performed their study in non-rheumatic Caucasian
individuals while we assessed Spanish RA patients with a
chronic inflammatory disease. Therefore, while in patients
with RA the presence of a chronic inflammatory burden
(among other factors) may lead to accelerated atheroscler-
osis, it may not be the case for the development of athero-
sclerosis in healthy individuals. Thus, differences in the
mechanisms implicated in the pathogenesis of atheroscler-
osis may account for these results. However, further inde-
pendent replication studies are required to confirm our
results in patients with RA.
Conclusion
Our results indicate that the ZC3HC1 rs11556924 poly-
morphism is associated with subclinical atherosclerosis
in RA.
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